First patient fitted with Carmat artificial heart dies
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The first patient fitted with an artificial heart made by the French company Carmat has died, the hospital that had performed the transplant in December said on Monday.
The 76-year-old man died on Sunday, 75 days after the operation, the Georges Pompidou European Hospital in Paris said in a statement, adding that the cause of his death could not be known for sure at this stage.
When he was fitted with the device, the man was suffering from terminal heart failure - when the sick heart can no longer pump enough blood to sustain the body - and probably had only a few weeks, or even days, to live.
Representatives of Carmat could not immediately be reached for comment.
The bioprosthetic organ product is designed to replace the real heart for up to five years, mimicking nature's work using biological materials and sensors. It is aimed at helping the thousands of patients who die each year while awaiting a donor, and reducing the side-effects associated with transplants.
The clinical trial will be considered a success if patients survive with the implant for at least a month.
If it passes the test, the device will then be fitted into about 20 patients with less severe heart failure.
"The doctors directly involved in the post-surgical care wish to highlight the value of the lessons learned from this first clinical trial, with regard to the selection of the patient, his surveillance, the prevention and treatment of difficulties encountered," the hospital said in its statement.
Reuters
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments